88 completed, 7 terminated, 2 withdrawn, 1 recruiting. 61 Phase 3, 18 Phase 4, 16 Phase 2, 2 Not applicable, 1 Phase 1.
Follow Duration of Therapy: new trials by email Literature Review of Duration of Therapy trials Research Report on Duration of Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of Uncomplicated Candidemia Therapy Duration in Children and Adults therapy duration - Invasive Candidiasis | Not applicable | Recruiting | Arkansas Children's Hospital Research Institute | 420 | 2023-09-08 | 2026-10-30 |
| Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections Duration of therapy - Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection | Not applicable | Terminated | Hospital Moinhos de Vento | 107 | 2022-01-27 | 2024-03-06 |
| To Evaluate the Impact of MRSA Nasal Screen Implementation. Duration of therapy, Direct Cost, Pharmacokinectic Monitoring - MRSA | Completed | Methodist Health System | 21 | 2019-10-01 | 2026-08-05 | |
| Effect of MK0524A on Flushing Caused by Niacin (0524A-056) MK0524A, /Duration of Treatment : 4 Weeks, Comparator : niacin /Duration of Treatment : 1 Weeks - Flushing | Phase 3 | Completed | Merck Sharp & Dohme LLC | 330 | 2007-04-01 | 2017-02-17 |
| A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092) MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days, Comparator: amikacin / Duration of Treatment: 3 Days, Comparator: tazocin / Duration of Treatment: 3 Days - Infection, Pneumonia | Phase 4 | Completed | Merck Sharp & Dohme LLC | 120 | 2006-11-01 | 2017-02-17 |
| Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED) MK0928 / Duration of Treatment : 8 Weeks - Primary Insomnia | Phase 3 | Terminated | H. Lundbeck A/S | 138 | 2006-09-01 | 2015-01-14 |
| Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122) MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks, Comparator: atorvastatin / Duration of Treatment: 6 Weeks - Cardiovascular Diseases, Diabetes Mellitus | Phase 3 | Terminated | Organon and Co | 550 | 2006-09-01 | 2024-08-15 |
| Effectiveness of Smecta in Combination With Oral Rehydration in the Treatment of Acute Watery Diarrhoea in Infants and Children Smecta (Diosmectite), duration of treatment - 7 days - Diarrhoea | Phase 3 | Completed | Ipsen | 302 | 2006-07-01 | 2019-11-22 |
| Effectiveness of Smecta in the Treatment of Acute Diarrhoea in Children Smecta (Diosmectite), duration of treatment - 7 days - Diarrhoea | Phase 3 | Completed | Ipsen | 300 | 2006-06-01 | 2019-11-22 |
| An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325) MK0954, losartan potassium / Duration of Treatment - 12 weeks - Hypertension | Phase 3 | Terminated | Organon and Co | 11 | 2006-03-13 | 2024-08-15 |
| Evaluate the Safety and Efficacy of Caspofungin Acetate as Empirical Therapy in Chinese Adults With Persistent Fever and Neutropenia (0991-055) MK0991, caspofungin acetate / Duration of Treatment: - Fungal Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 131 | 2006-03-01 | 2015-12-17 |
| Upper GI Handling of Branded vs. Generic Alendronate MK0217, alendronate sodium / Duration of Treatment: 1 Month, Comparator: Alendronate-Teva / Duration of Treatment: 1 Month - Osteoporosis | Phase 3 | Completed | Merck Sharp & Dohme LLC | 25 | 2005-12-01 | 2006-11-17 |
| Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia EDP-420 / Duration of Treatment - 3 days, Telithromycin / Duration of Treatment - 7 days - Community Acquired Pneumonia | Phase 2 | Unknown | Enanta Pharmaceuticals, Inc | 250 | 2005-12-01 | 2006-09-19 |
| SINGULAIR (R) as Complementary Therapy to Fixed Association Regimen (0476-363) MK0476, montelukast sodium / Duration of Treatment: 8 Weeks - Asthma | Phase 3 | Completed | Organon and Co | 198 | 2005-11-01 | 2024-08-15 |
| MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED) MK0928, gaboxadol / Duration of Treatment 3 Weeks, Placebo / Duration of Treatment 3 Weeks - Primary Insomnia | Phase 2 | Completed | H. Lundbeck A/S | 520 | 2005-11-01 | 2015-01-14 |
| Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED) MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose), Placebo / Duration of Treatment: 2 days for screening period - Primary Insomnia | Phase 2 | Terminated | H. Lundbeck A/S | 50 | 2005-11-01 | 2015-01-14 |
| Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323) MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks - Hypertension | Phase 3 | Completed | Organon and Co | 62 | 2005-09-01 | 2024-08-15 |
| Quality of Life With Arcoxia in Women With Dysmenorrhea (0663-094) MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days - Pain | Phase 4 | Completed | Organon and Co | 337 | 2005-09-01 | 2024-08-15 |
| To Evaluate the Inflammatory Markers in Adult Patients With Asthma Associated With Allergic Rhinitis Receiving Montelukast Therapy (0476-366) MK0476, montelukast sodium / Duration of Treatment: 12 Weeks - Asthma | Phase 3 | Completed | Organon and Co | 58 | 2005-08-01 | 2024-08-15 |
| To Evaluate the Treatment Effect of an Anti-Infective Agent for Different Kinds of Infections (0826-052) MK0826, ertapenem sodium / Duration of Treatment: 14 Days - Infection, Pneumonia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 30 | 2005-07-01 | 2017-02-17 |
Showing 20 of 99. Sign in to see all of them.
Asthma (10) · Hypercholesterolemia (8) · Hypertension (6) · Sleep Initiation and Maintenance Disorders (6) · Diabetes Mellitus, Type 2 (5) · Migraine Disorders (4) · Osteoporosis (4) · Osteoporosis, Postmenopausal (4) · Flushing (3) · Infections (3) · Nausea (3) · Osteoarthritis (3) · Pain (3) · Vomiting (3) · Acromegaly (2)
Organon and Co (55) · Merck Sharp & Dohme LLC (30) · H. Lundbeck A/S (6) · Ipsen (4) · Arkansas Children's Hospital Research Institute (1) · Enanta Pharmaceuticals, Inc (1) · Hospital Moinhos de Vento (1) · Methodist Health System (1)
United States (3) · Australia (1) · Brazil (1) · Germany (1) · Italy (1) · Malaysia (1) · Peru (1) · Taiwan (1)
Alexandre Prehn Zavascki (1) · Brian Fisher, DO (1) · Daniel Betina (1) · William J Steinbach, MD (1)
PMID 12612294, PMID 12937228, PMID 16291062, PMID 17196507, PMID 17392721, PMID 17468348, PMID 17502347, PMID 17588299, PMID 17985033, PMID 18566548, PMID 18922570, PMID 18946234, PMID 19059567, PMID 19236277, PMID 19236279, PMID 19332468, PMID 19487264, PMID 19505910, PMID 19542735, PMID 19949604, PMID 20001655, PMID 20191935, PMID 20200926, PMID 20589977, PMID 20601389, PMID 21086246, PMID 21239405, PMID 21300618, PMID 21304095, PMID 21307649, PMID 21358415, PMID 21720264, PMID 22243363, PMID 22695506, PMID 22753219, PMID 23062719, PMID 23403268, PMID 24379001, PMID 24723582, PMID 24798675, PMID 25340854, PMID 25633134, PMID 26056336, PMID 26089332, PMID 26378687, PMID 29151037, PMID 29176391, PMID 29474712, PMID 29580174, PMID 30676480
2004 (1), R01AI170385 (1)